首页> 外文期刊>Journal of the Royal Society of Medicine >Prior disclosure need not be a problem for journals
【24h】

Prior disclosure need not be a problem for journals

机译:期刊不必事先披露

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In their recent editorial in JRSM, Liz Wager and Kamran Abbasi boldly suggest that medical journal editors have ‘deserted the moral high ground’ in failing to welcome legal requirements for publicly accessible reporting of clinical trial results.1,2 Trial researchers and sponsors may be interested to know of PLoS Medicine's policy on results disclosure. As set out in a recent editorial,3 we and the other PLoS journals support public disclosure of results of all clinical trials; our guidelines to authors state that: ‘Prior disclosure of results on a public website such as clinicaltrials.gov will not affect the decision to peer review or acceptance of papers in PLoS journals’.4 We hope that editors of journals will pay close attention to Wager and Abbasi's argument that journal articles can provide context, commentary and interpretation of the results of clinical trials; moreover, we propose that journals should provide mechanisms for establishing the quality of research and include similar statements to that of PLoS Medicine in their editorial policies.
机译:Liz Wager和Kamran Abbasi在其最近发表的JRSM社论中大胆建议,医学期刊编辑在不欢迎法律要求公开发表临床试验结果的法律要求时,已经“放弃了道德制高点”。1,2有兴趣了解PLoS Medicine的结果披露政策。正如最近的社论3所述,我们和其他PLoS期刊都支持公开披露所有临床试验结果;我们的作者指南指出:“事先在公共网站(例如Clinicaltrials.gov)上披露结果不会影响对PLoS期刊进行同行评审或接受论文的决定。” 4我们希望期刊编辑应密切关注Wager和Abbasi认为期刊文章可以提供临床试验结果的背景,评论和解释;此外,我们建议期刊应提供建立研究质量的机制,并在其编辑政策中包括与PLoS Medicine类似的陈述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号